I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ACR 2026

We will be contributing to topics related to
-
03:30 PM
Duration 120mins Orlando, USA
Obinutuzumab Achieves Sustained Glucocorticoid Control: An Exploratory Analysis From a Phase III Trial in Active Systemic Lupus Erythematosus
Luca Iaccarino, Włodzimierz Samborski, Sunil Kumar, Asokan Naidoo, Bongin Yoo, Sonja Nick, Oliver Meier, William F. Pendergraft III, Jay P. Garg, Edward M. Vital, Ronald Van Vollenhoven, Richard A. Furie, Eric Morand
Duration 120mins Orlando, USA
Unmet Need and Treatment Disparities Among Lupus Patients With Medicaid Insurance in the United States
Jesse Sussell, Zhiyu Xia, Rongrong Wang, William F. Pendergraft III, Maria Dall’Era
03:30 PM
Duration 120mins Orlando, USA
Association Between Sustained Peripheral CD19+ B Cell Depletion and Clinical Efficacy of Obinutuzumab in Lupus Nephritis: Post-hoc analyses of the Phase 3 Trial
Richard A. Furie, Olivia Hwang, Bongin Yoo, William F. Pendergraft III, Theodore A. Omachi, Frederic Boissard, Edward M. Vital, Brad H. Rovin, Harini Raghu
Duration 120mins Orlando, USA
Obinutuzumab Facilitates Tubular Repair in Lupus Nephritis Independently of Histologic or Clinical Response: Post Hoc Analyses of Urine EGF in a Phase III Trial
Harini Raghu, Holly J. Clarke, Juan M. Mejia-Vilet, Ben Lanza, Peiqing Yu, Theodore A. Omachi, William F. Pendergraft III, Brad H. Rovin
Duration 120mins Orlando, USA
Obinutuzumab Reduces Fatigue and Improves Health-Related Quality of Life: Results from a Phase III Trial in Systemic Lupus Erythematosus
Eric Morand, Laurent Arnaud, Jeannette Andersen, Marta Mosca, Luca Iaccarino, Josefina Cortés-Hernández, Sandrine Jousse-Joulin, Olga Mitrofanova, Oliver Meier, Gene Wallenstein, Peiqing Yu, Jay P. Garg, Maria Dall’Era, Richard A. Furie, Edward M. Vital, Anca D. Askanase, Ronald Van Vollenhoven
Duration 120mins Orlando, USA
Impact of Lupus Nephritis Flares on Healthcare Utilization: A Retrospective Cohort Study in the United States Between 2016 and 2025
Jesse Sussell, Jiying Zou, Huong Trinh, Shu Wang, Anisha M. Patel, William F. Pendergraft III, Lisa Lindsay
03:45 PM
Duration 15mins Orlando, USA
Obinutuzumab Induces Histologic Remission and Deep Kidney Parenchymal B-cell Depletion in Patients With Lupus Nephritis: Exploratory Analyses From a Phase III Trial
Richard A. Furie, Brad H. Rovin, Elsa Martins, Cary D. Austin, Harini Raghu, Caleb Chan, Patrick S. Chang, Jay P. Garg, Valeria Alberton, Mittermayer B. Santiago, Gustavo Aroca-Martínez, Fedra I. Palazuelos, Teresa Baczkowska, Jose Alfaro, Jorge Ravelo-Hernández, Luis F. Pinto, Eduardo H. Albiero, Christopher Larsen, Bongin Yoo, Jennifer Pulley, Andrew Thorley, Thomas Schindler, Theodore A. Omachi, William F. Pendergraft, Ana Malvar
03:30 PM
Duration 120mins Orlando, USA
Obinutuzumab Induces Rapid and Durable Resolution of Clinical Disease Activity Across Active Clinical SLEDAI-2K Organ Domains in Patients With Systemic Lupus Erythematosus
Edward M. Vital, Elisa Gremese, Katarzyna Romanowska-Próchnicka, Ingrid Louw, Peiqing Yu, Oliver Meier, Olga Mitrofanova, Theodore A. Omachi, Jay P. Garg, Eric Morand, Richard A. Furie, Joan T. Merrill, Anca D. Askanase
Coming soon